286
Participants
Start Date
April 6, 2025
Primary Completion Date
June 15, 2029
Study Completion Date
December 31, 2029
Standard Therapy
For patients with negative EGFR/ALK mutation, adjuvant chemotherapy or adjuvant chemotherapy combined with immunotherapy was administered, for patients with positive EGFR/ALK mutation, targeted therapy was administered.
Adaptive Therapy
Patients will be under close MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
RECRUITING
Peking University Cancer Hospital & Institute, Beijing
Tianjin Chest Hospital
OTHER
Peking University First Hospital
OTHER
The First Hospital of Jilin University
OTHER
Beijing Friendship Hospital
OTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Geneplus-Beijing Co. Ltd.
INDUSTRY
Peking University Cancer Hospital & Institute
OTHER